There are indeed many, many, many JUNK codons in this nonsense region mostly tied to MUTATIONS of normal genes which get passed by or pushed out of the VITAL regions of genetic code.
ALMOST ALL OF THESE MUTATIONS ARE NOT HARMFUL-----THEY DO NOT KILL US-----
So, locating a gene codon thought to be tied to CANCER--------that's fine, but there are a multitude of other codons along this DNA/RNA strand that are also tied to cancer-----that are necessary for that cancer to activate. Today, these genetic research studies have only identified POSSIBLE disease vector sites---------and are nowhere near finding all that is support codons many likely will be found in this NONSENSE REGION.
Genetic Mutation ‹ OpenCurriculum
Mutations found in the DNA of cancer cells typically affect two general classes of genes: oncogenes and tumor suppressor genes.
In “normal,” non-cancerous cells, the products of proto-oncogenes promote cell growth and mitosis prior to cell division; thus, proto-oncogenes encode proteins needed for normal cellular functions.
This is critical information because when we read articles telling us that our DNA is 80-90% JUNK -------global banking 1% are PRETENDING that these regions are OK for very harmful testing as with DEREGULATION of genetic codons and surrounding regions.
Think of this in another way-----the ATOMIC BOMB was developed by dropping over and over onto ISLANDS we were told were not inhabited---therefor it was OK to DEREGULATE that island ------this is what global banking 1% FAKE NEWS MEDIA FAKE ACADEMIC DATA are telling us.
THIS IS ALL NONSENSE ------IT IS ALL JUNK ----SO, IF WE ARE DEREGULATING, PRACTICING INSERTIONS AND DELETIONS ------TRYING TO INSTALL HUMAN GENES IN ANIMALS -----THIS ISLAND IS NOT INHABITED.
Below we see this same research this time on RNA------same genetic apparatus and we see scientists are finding COMPLEX AND DIVERSE FUNCTIONS in these regions.
DEREGULATING THESE NONSENSE REGIONS MAY WELL BE INTERFERING WITH SUPPORT CODONS WHICH PROVIDE NORMAN BODY FUNCTIONS-----ERGO, DISEASE/ILLNESS/DEATH.
for Long Noncoding RNAs
and Peter Fraser
Nuclear Dynamics and Function Laboratory, The Babraham Institute, Babraham Research Campus, Cambridge CB22 3AT, UK
The mysterious secrets of long noncoding RNAs, often referred to as the Dark Matter of the
genome, are gradually coming to light.
Several recent papers dig deep to reveal surprisingly
complex and diverse functions of these enigmatic molecules'.
The other issue posted yesterday tied to global banking 1% medical corporations having successfully inserted HUMAN TO ANIMAL genome has these problems.
First, deleting a mouse codon for example identified as an ONCOGENE-------and replacing it with a HUMAN codon identified as an ONCOGENE -----is about as APPLES TO ORANGES as any scientific process can be. If a scientist is doing a MOUSE STUDY then MOUSE DNA CODONs must be used. As we said, our animals have the same industrial toxin exposure----so they have CANCER CODONS on their DNA. What needs to be done first is to determine all the VARIABLES tied to one kind of CANCER using MOUSE DNA.
Can HUMAN DNA be inserted into MOUSE DNA? We are sure this has been done. How in the world does one determine whether that HUMAN insertion prevented or reduced ONE CANCER in ONE MOUSE?
These kinds of experiments have a goal of DEREGULATING a species' DNA just to allow these insertions which GOD'S NATURAL LAW would not permit. This is of little value to human medical welfare.
So, why are far-right wing global banking 1% BARBER SURGEONS doing this? They want to PRETEND human research is now being done in animals PRETENDING the results provide REAL DATA.
Animals That Share Human DNA Sequences
Written by Lori Garrett-Hatfield
With the discovery of the structure of deoxyribonucleic acid, and the technology to sequence the genomes of both humans and animals, it is no surprise to find that we have a lot in common with our animal friends. How much humans have in common with animals may come as a bit of a shock. While it is understandable that we share DNA with our cousins the apes, we also share DNA with other, less simian animals.
Apes, Monkeys, And Humans
Humans are most closely related to the great apes of the family Hominidae. This family includes orangutans, chimpanzees, gorillas, and bonobos. Of the great apes, humans share 98.8 percent of their DNA with bonobos and chimpanzees. Humans and gorillas share 98.4 percent of their DNA. Once the apes are not native to Africa however, the differences in DNA increase. Humans and orangutans share 96.9 percent of their DNA. Humans and monkeys share approximately 93 percent.
Humans and mice share nearly 90 percent of human DNA. This is important because mice have been used in laboratories as experimental animals for research into human disease processes for years. Mice are currently used in genetic research to test gene replacement, and gene therapy because they have similar gene types to those of humans and will have similar reactions to diseases and disease processes.
Humans and dogs share 84 percent of their DNA, which again, makes them useful animals to study human disease processes. Researchers are particularly interested in specific diseases that affect both dogs and humans. Retinal disease, cataracts, and retinitis pigmentosa blind both humans and their canine friends, and scientists study and research treatments of the disease in dogs in the hope that the same treatments will be beneficial to humans. Dogs are also being studied and treated for cancer, epilepsy, and allergies, to find more successful treatment for humans.
Of course, humans, dogs, mice and apes are going to have DNA in common. They are all mammals. Humans and birds are a different matter. Yet they, too, share a lot of DNA -- 65 percent. Understanding the similarities and differences between human and avian DNA is important. First, because chickens make proteins, such as interferon, that are helpful to human immunity, and need to be further studied. Second, because viruses like the ones that cause the flu cross between birds and humans and need to be studied so that vaccines can be invented and improved.
The reason REAL LEFT SOCIAL PROGRESSIVE research academics created this structure for CLINICAL TRIALS last century was to meet the obligation of DO NO HARM-----HIPPOCRATIC OATH-------you know, those ETHICS AND MORALS of medicine for thousands of years.
Most clinical trials had 3 phases------the earliest were research on lab animal systems-----that research included several kinds of animals from squid to worms----from mice to dogs------BEFORE even thinking of taking these studies to HUMANS.
SCIENTIFIC METHOD------ELIMINATING/CONTROLLING VARIABLES-------NEEDED FOR VALID STUDY CONCLUSIONS.
All last century these scientific BASIC SCIENCE research spent several decades on studying animal models sometimes concluding the HYPOTHESIS WAS NOT CORRECT------so the research did not proceed to next PHASE OF CLINICAL TRIAL.
It has been clear for thousands of years that medical research done on animals is preliminary------not conclusive. Animal systems operate differently then human systems ergo-----we cannot eliminate HUMAN PHASES of CLINICAL TRIALS.
What Happens in a Clinical Trial?
What are clinical trials?
Clinical trials are a way to test new methods of diagnosing, treating, or preventing health conditions. The goal is to determine whether something is both safe and effective.
A variety of things are evaluated through clinical trials, including:
- medication combinations
- new uses for existing medications
- medical devices
If the preclinical research is promising, they move forward with a clinical trial to see how well it works in humans. Clinical trials happen in several phases during which different questions are asked. Each phase builds on the results of previous phases.
Keep reading to learn more about what happens during each phase. For this article, we use the example of a new medication treatment going through the clinical trial process.
What happens in phase 0?
Phase 0 of a clinical trial is done with a very small number of people, usually fewer than 15. Investigators use a very small dose of medication to make sure it isn’t harmful to humans before they start using it in higher doses for later phases.
If the medication acts differently than expected, the investigators will likely to do some additional preclinical research before deciding whether to continue the trial.
What happens in phase I?
During phase I of a clinical trial, investigators spend several months looking at the effects of the medication on about 20 to 80 people who have no underlying health conditions.
This phase aims to figure out the highest dose humans can take without serious side effects. Investigators monitor participants very closely to see how their bodies react to the medication during this phase.
While preclinical research usually provides some general information about dosing, the effects of a medication on the human body can be unpredictable.
In addition to evaluating safety and ideal dosage, investigators also look at the best way to administer the drug, such as orally, intravenously, or topically.
According to the FDA, approximately 70 percent of medications move on to phase II.
What happens in phase II?
Phase II of a clinical trial involves several hundred participants who are living with the condition that the new medication is meant to treat. They’re usually given the same dose that was found to be safe in the previous phase.
Investigators monitor participants for several months or years to see how effective the medication is and to gather more information about any side effects it might cause.
While phase II involves more participants than earlier phases, it’s still not large enough to demonstrate the overall safety of a medication. However, the data collected during this phase helps investigators come up with methods for conducting phase III.
The FDA estimates that about 33 percent of medications move on to phase III.
What happens in phase III?
Phase III of a clinical trial usually involves up to 3,000 participants who have the condition that the new medication is meant to treat. Trials in this phase can last for several years.
The purpose of phase III is to evaluate how the new medication works in comparison to existing medications for the same condition. To move forward with the trial, investigators need to demonstrate that the medication is at least as safe and effective as existing treatment options.
To do this, investigators use a process called randomization. This involves randomly choosing some participants to receive the new medication and others to receive an existing medication.
Phase III trials are usually double-blind, which means that neither the participant nor the investigator knows which medication the participant is taking. This helps to eliminate bias when interpreting results.
The FDA usually requires a phase III clinical trial before approving a new medication. Due to the larger number of participants and longer duration or phase III, rare and long-term side effects are more likely to show up during this phase.
If investigators demonstrate that the medication is at least as safe and effective as others already on the market, the FDA will usually approve the medication.
Roughly 25 to 30 percent of medications move on to phase IV.
What happens in phase IV?
Phase IV clinical trials happen after the FDA has approved medication. This phase involves thousands of participants and can last for many years.
Investigators use this phase to get more information about the medication’s long-term safety, effectiveness, and any other benefits.
When we discuss CLINTON era use of EXECUTIVE ORDER to pretend our entire FEDERAL AND US CONSTITUTIONAL history could be ignored-------this included those regulations tied to our MEDICAL RESEARCH -----CLINICAL TRIALS------and FDA approval of PHARMA, MEDICAL PROCEDURES, and DEVICES.
What has our US 99% of WE THE PEOPLE seen since 1990s? We have watched as CLASS ACTION LAWSUITS soared because US citizens were being harmed/killed by the hundred millions these few decades.
THIS IS WHY THOSE RATES SOARED.
So, CLINTON era started ignoring all these public interest public safety guidelines inside US while global medical corporations went to overseas FOREIGN ECONOMIC ZONES to create scientific research minus SCIENTIFIC METHOD. It took BUSH AND OBAMA era to defund, dismantle this entire structure and this is why TRUMP and his FDA are eliminating all these protections completely.
'Clinton Retains Bush Appointee As F.D.A. Chief
By PHILIP J. HILTSFEB. 27, 1993'
BIO Calls on President Clinton to Sign FDA Reform Bill Into Law
(WASHINGTON, DC, November 10, 1997)...Carl B. Feldbaum, president of the Biotechnology Industry Organization (BIO), today issued the following statement in response to Congressional passage of legislation which reauthorizes the Prescription Drug User Fee Act (PDUFA) and modernizes the Food and Drug Administration (FDA).
Passage of this legislation today `turns the clock ahead' to help the next generation of modern medicines get to patients sooner and more efficiently. Several hundred biotech products are in clinical trials right now at the FDA, many for medical conditions such as Alzheimer's and breast and ovarian cancers, for which there are no adequate treatments. With this bill we have achieved a regulatory process for the beginning of the next century that recognizes both the advances in our technology and the need to bring biotech products to the market, and even more critically to patients as soon as possible. Passage of this bill also represents a new, successful partnership between our biotech industry researchers and government regulators at the FDA. Instead of an adversarial or even confrontational posture in which both our research companies and patients lose, this bill represents over two years of negotiations which will result in the ability of biotechnology companies to more efficiently develop their scientific breakthroughs into vital medical products. Put simply, a modern FDA will greatly enhance our industry's potential to develop new therapies and cures. "This legislation, which also reauthorizes PDUFA, will provide resources for additional drug reviewers and an electronic FDA. In addition, it helps cut the red tape on clinical trials by modernizing several 35-year-old FDA regulations. For example, the manner by which manufacturing changes are reported to the FDA will be streamlined, greatly reducing bureaucratic impediments against improving manufacturing processes. In very human terms this legislation means renewed hope for millions of patients, and their families, who suffer from heart disease, various cancers, cystic fibrosis, multiple sclerosis and other debilitating and deadly diseases. "We call upon President Clinton to sign this legislation with all deliberate speed."
The Biotechnology Industry Organization (BIO) represents over 745 biotechnology companies, academic institutions, and state biotechnology centers in 46 states and 25 nations. BIO members are involved in the research and development of health care, agricultural and environmental biotechnology products.
TRANS PACIFIC TRADE PACT ---TPP, is that ONE WORLD ONE GOVERNANCE health policy pushed by WORLD BANK/WORLD HEALTH ORGANIZATION with goals of killing all of our US sovereign regulatory structures -----especially all our strong protections surrounding PUBLIC HEALTH AND WELFARE. While CLINTON/BUSH spent these few decades defunding and dismantling these Federal PUBLIC HEALTH structures -----as FDA oversight and accountability actually holding institutions and corporations responsible to PUBLIC SAFETY AND WELFARE-----what is MOVING FORWARD today is bringing these overseas FOREIGN ECONOMIC ZONE economic and social structures to US FOREIGN ECONOMIC ZONES.
ORGAN HARVESTING CARTELS et al thrived in these overseas third world nations because of TTP deregulation of medical industry. We KNOW these bio-genetic research tied to DEREGULATION of genome---tied to insertions and deletions -----have already been happening overseas to HUMAN FETUSES and we KNOW the rate of harm and death from these experiments are HIGH.
THIS IS WHAT OBAMA ERA AFFORDABLE CARE ACT POLICY INSTALLED AS WELL------ACA STATES THE CHEAPEST ROUTE CAN BE TAKEN FOR MEDICAL CORPORATIONS IN PROTECTING AND MAXIMIZING PROFITS.
The Trans-Pacific Partnership: A Threat To Global Health?
May 8, 2015
Lost in the political discussions over the passage of the Trans-Pacific Partnership (TPP)—a trade agreement currently being negotiated in secret between the U.S. and 11 other Pacific-Rim nations--is the very real negative impact it would have on global health.
Doctors Without Borders/Médecins Sans Frontières (MSF) works in over 60 countries, and our medical teams rely on access to affordable medicines and vaccines. We are deeply concerned that the TPP, in its current form, will lock-in high, unsustainable drug prices, block or delay the availability of affordable generic medicines, and price millions of people out of much-needed medical care.
The public health repercussions of this deal could be massive. The negotiating countries represent at least 700 million people, and U.S. negotiators refer to the TPP as a “blueprint” for future trade deals. The TPP attempts to rewrite existing global trade rules and would dismantle legal flexibilities and protections afforded for public health.
We have concerns with several U.S. government demands in the TPP. For example, the TPP would lower the standard for patentability of medicines. It would force TPP governments to grant pharmaceutical companies additional patents for changes to existing medicines, even when the changes provide no therapeutic benefit to patients. These provisions would facilitate “evergreening” and other forms of abuse of the patent system by lengthening monopolies and delaying access to generic competition.
Another concerning provision in the TPP involves so-called "data exclusivity" for biologics, a new class of medicines that includes vaccines and drugs used for cancer and multiple sclerosis treatment. Data exclusivity blocks competing firms from using previously generated clinical trial data to gain approval for generic versions of these drugs and vaccines. If pharmaceutical companies have their way, the TPP will block generic producers of biologics from entering the market for at least 12 years, during which patients would be forced to endure astronomical prices.
The rationale given for such an exclusivity period is that it will promote innovation by allowing originator companies enough time to charge high prices and recoup their research and development investment. This simply isn’t supported by the evidence. On the contrary, the Federal Trade Commission finds that no years of data exclusivity were necessary to promote innovation in biologic drugs.
Twelve years of data exclusivity is not only unprecedented in any trade agreement, it is not the law in any of the TPP negotiating countries outside of the U.S., and it would keep lifesaving medicines out of reach of millions of people. The Obama Administration has actually called for data exclusivity to be reduced to seven years at home, so it is puzzling that the U.S. Trade Representative would be aggressively pushing for these terms in the TPP.
These provisions and others currently included in the TPP are at direct odds with the U.S. government’s own long-standing commitments to global health. U.S. taxpayer-supported initiatives like PEPFAR, the Global Fund for AIDS, TB and Malaria, and Gavi, the Vaccine Alliance, rely on affordable, generic medicines in order to operate effectively.
Research And Development
As an organization caring for patients worldwide, Doctors Without Borders understands that there should be incentives to recover research and development investments and to promote innovation. Unfortunately, the public is in the dark on what this research and development truly costs. We are told that it costs billions to research and develop a new medicine, although a significant amount of early research and development actually happens at publicly funded centers and universities.
We are told that the only way to ensure that people receive the medicines they need is by increasing intellectual property provisions, such as those encapsulated in the TPP. In reality, the existing monopoly-based innovation system that the TPP is attempting to standardize has left us with more patents and fewer medical breakthroughs.
The most recent and dramatic example of this failure in innovation played out just last year, when Ebola raged through West Africa. Doctors Without Borders and other global health actors were ill-equipped to fight a disease that was identified 40 years ago but for which there are still no adequate diagnostics, treatments, or vaccines.
As TPP countries aim to conclude negotiations in the next few months, it is essential that the United States and other negotiating countries work to protect existing access to medicines' safeguards and to promote a public-health driven biomedical innovation system.
The reason DR LANGER with the MIT research institute as too HARVARD think it is OK to MOVE FORWARD with these bio-genetic research in HUMANS is as he states it will only harm or kill individual people and not harm the HUMAN RACE. MIT as we discuss often has been raging far-right wing global banking 1% OLD WORLD KINGS KNIGHTS OF MALTA ------and indeed the people pushing all this forward----those .00001% which we call the global 1% OLD WORLD KINGS------having that century-old goal of TRANSHUMANIST CREATIONISM-----
READING TO HUMAN GENOME finished last decade means A CENTURY or more of BASIC SCIENCE research will be necessary before ANY conclusive applications in this area can be released to HUMAN PATIENTS and we insist that include our 99% of CITIZENS persuaded to VOLUNTEER as research clients.
"It has been only about a decade since we first read the human genome," he writes. "We should exercise great caution before we begin to rewrite it."
Remember, DAN BROWN'S INFERNO-------filled with conspiracy theories of depopulation opened the door to what is indeed the goal of a global 1% buying those DR NOs. The reference below that these research pose no threat to HUMAN RACE----the damage only to individuals is a FALSE FLAG.
'Unlike the kind of embryo editing that could lead to permanent changes in the human race, these edits would be made in babies, children, or adults. That means, Lander writes, "they pose no unique ethical issues because they affect only a patient's own [ordinary] cells."'
The idea that global banking 1% will develop the basic science ------will create medical treatments which actually do eliminate ANY ONE DISEASE VECTOR ------much less 5 ------ANYTIME THIS CENTURY-------is FAKE NEWS.
5 terrible illnesses that genetic engineering could eliminate forever
Lauren F Friedman
Jun. 5, 2015, 10:12 AM
Eric S. Lander.
Maggie Bartlett / Wikimedia Commons
The dangers of editing the human genome are well known. The significance of changing small aspects of people, tweaking them to our liking, means that even a mostly fruitless attempt to edit human embryos sparked widespread criticism — and fear that designer babies could be right around the corner.But the potential to use these same technologies to cure intractable diseases is huge.
In a recent essay for the New England Journal of Medicine, Eric S. Lander, the founding director of the Broad Institute and a professor at Harvard Medical School and MIT, clearly expresses the importance of not being hasty or foolish as this transformative research moves forward.
"It has been only about a decade since we first read the human genome," he writes. "We should exercise great caution before we begin to rewrite it."
But he also notes that while more discussion and regulation is necessary before these tools become a free-for-all, "genome editing also holds great therapeutic promise."
Specifically, he mentions five diseases that could be completely eliminated with gene-editing technology (once that technology becomes much more accurate and reliable than it is today):
- HIV. "Physicians might edit a patient's immune cells to delete the CCR5 gene, conferring the resistance to HIV carried by the 1% of the US population lacking functional copies of this gene," he writes.
- Some forms of genetic blindness. Inactivating a certain variant of a gene in the retinal cells of the eye could stop some types of inherited, progressive blindness in their tracks, Lander suggests.
- Familial hypercholesterolemia. An inherited condition, familial hypercholesterolemia can lead to extremely high levels of "bad" cholesterol and heart attacks at a young age. Editing liver cells could fix this inherited disorder, Lander suggests.
- Sickle-cell anemia. Lander suggests that editing blood stem cells could cure this disease, which affects about 100,000 Americans and can cause lifelong pain and even organ damage.
- Hemophilia. Another blood disorder that Lander says could be cured by editing blood stem cells, hemophilia causes frequent bruising, pain, and excessive bleeding because of low or no levels of the proteins needed to create clots. About one in 5,000 babies in the US is born with classic hemophilia.
Still, Lander points to "serious technical challenges" that would have to be overcome before any of these potential cures could be implemented. The technology is still a long way off from making these kinds of treatments a reality.